Technical Analysis for IBIO - iBio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| 20 DMA Resistance | Bearish | 3.56% | |
| Earnings Movers | Other | 3.56% | |
| Down 3 Days in a Row | Weakness | 3.56% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 15 hours ago |
| Up 2% | about 15 hours ago |
| Possible NR7 | about 16 hours ago |
| Possible Inside Day | about 16 hours ago |
| 20 DMA Support | about 19 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
iBio, Inc. Description
iBio, Inc., a biotechnology company, engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary iBioLaunch platform technology in the United States. Its product portfolio includes seasonal and H1N1 influenza vaccines for the seasonal influenza virus strains; pandemic avian influenza vaccine for the pathogenic avian influenza viruses; and therapeutic vaccines for human papilloma virus. The company also offers biodefense products, including oral anthrax booster vaccine candidates and candidate plague vaccines. In addition, it provides therapeutic protein product candidates comprising human alpha-galactosidase A for the treatment of Fabry disease; human C-1 esterase inhibitor for the treatment of hereditary angioedema; and human alpha-1 antitrypsin for treatment of disorders caused by a deficiency of alpha-1 antitrypsin. Further, the company offers vaccine enhancements through its iBioModulator platform. It has a license and collaboration agreement with Caliber Biotherapeutics, LLC for the development and production of recombinant plant-based biopharmaceuticals. The company is headquartered in Newark, Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Disorders Vaccines Influenza Vaccination Viruses Platform Technology Microbiology Angioedema Hereditary Angioedema Biodefense Influenza Vaccine Defense Products Seasonal Influenza Deficiency Fabry Disease Anthrax Avian Influenza Human Papilloma Virus Influenza Viruses Treatment Of Fabry Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.98 |
| 52 Week Low | 0.2 |
| Average Volume | 4,764,408 |
| 200-Day Moving Average | 1.04 |
| 50-Day Moving Average | 1.82 |
| 20-Day Moving Average | 1.85 |
| 10-Day Moving Average | 1.92 |
| Average True Range | 0.19 |
| RSI (14) | 50.00 |
| ADX | 15.49 |
| +DI | 23.81 |
| -DI | 19.63 |
| Chandelier Exit (Long, 3 ATRs) | 1.62 |
| Chandelier Exit (Short, 3 ATRs) | 2.20 |
| Upper Bollinger Bands | 2.06 |
| Lower Bollinger Band | 1.64 |
| Percent B (%b) | 0.57 |
| BandWidth | 22.40 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.0072 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.02 | ||||
| Resistance 3 (R3) | 2.01 | 1.97 | 1.99 | ||
| Resistance 2 (R2) | 1.97 | 1.93 | 1.97 | 1.98 | |
| Resistance 1 (R1) | 1.92 | 1.91 | 1.90 | 1.93 | 1.98 |
| Pivot Point | 1.88 | 1.88 | 1.87 | 1.88 | 1.88 |
| Support 1 (S1) | 1.83 | 1.84 | 1.81 | 1.84 | 1.78 |
| Support 2 (S2) | 1.79 | 1.82 | 1.79 | 1.78 | |
| Support 3 (S3) | 1.74 | 1.79 | 1.77 | ||
| Support 4 (S4) | 1.75 |
